ALNYLAM PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147.2 USD | +2.69% |
|
+1.02% | -23.06% |
| Apr. 08 | Sector Update: Health Care Stocks Flat to Higher Premarket Monday | MT |
| Apr. 08 | Sector Update: Health Care | MT |
Presenter SpeechChristine Lindenboom (Executives)Good evening, everyone. I'm Christine Lindenb...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
143.3
USD
Average target price
219.9
USD
Spread / Average Target
+53.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.91% | 18.12B | |
| +2.20% | 42.75B | |
| +47.70% | 41.61B | |
| +12.30% | 41.34B | |
| -8.83% | 26.59B | |
| +6.58% | 25.49B | |
| +30.28% | 12.24B | |
| -2.05% | 11.76B | |
| +8.99% | 11B | |
| -15.89% | 10.07B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
